Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Introduction: Advances in protein analysis for the clinical laboratory.

Literature DB >> 19910505

Introduction: Advances in protein analysis for the clinical laboratory.

Glen L Hortin¹, Steven A Carr, N Leigh Anderson.

Abstract

Entities: Chemical Disease Gene Species

Mesh：

Substances：
Biomarkers
Proteins

Year: 2009 PMID： 19910505 PMCID： PMC2865472 DOI： 10.1373/clinchem.2009.132803

Source DB: PubMed Journal: Clin Chem ISSN： 0009-9147 Impact factor: 8.327

× No keyword cloud information.

13 in total

Review 1. The human plasma proteome: history, character, and diagnostic prospects.

Authors: N Leigh Anderson; Norman G Anderson
Journal: Mol Cell Proteomics Date: 2002-11 Impact factor: 5.911

2. Can mass spectrometric protein profiling meet desired standards of clinical laboratory practice?

Authors: Glen L Hortin
Journal: Clin Chem Date: 2005-01 Impact factor: 8.327

3. Proteomics: a new diagnostic frontier.

Authors: Glen L Hortin; Saeed A Jortani; James C Ritchie; Roland Valdes; Daniel W Chan
Journal: Clin Chem Date: 2006-05-04 Impact factor: 8.327

Review 4. Protein biomarker discovery and validation: the long and uncertain path to clinical utility.

Authors: Nader Rifai; Michael A Gillette; Steven A Carr
Journal: Nat Biotechnol Date: 2006-08 Impact factor: 54.908

Review 5. The blood peptidome: a higher dimension of information content for cancer biomarker discovery.

Authors: Emanuel F Petricoin; Claudio Belluco; Robyn P Araujo; Lance A Liotta
Journal: Nat Rev Cancer Date: 2006-11-09 Impact factor: 60.716

6. Quantification of thyroglobulin, a low-abundance serum protein, by immunoaffinity peptide enrichment and tandem mass spectrometry.

Authors: Andrew N Hoofnagle; Jessica O Becker; Mark H Wener; Jay W Heinecke
Journal: Clin Chem Date: 2008-09-18 Impact factor: 8.327

Review 7. The MALDI-TOF mass spectrometric view of the plasma proteome and peptidome.

Authors: Glen L Hortin
Journal: Clin Chem Date: 2006-04-27 Impact factor: 8.327

8. Protein quantitation through targeted mass spectrometry: the way out of biomarker purgatory?

Authors: Steven A Carr; Leigh Anderson
Journal: Clin Chem Date: 2008-11 Impact factor: 8.327

9. Peptides generated ex vivo from serum proteins by tumor-specific exopeptidases are not useful biomarkers in ovarian cancer.

Authors: John F Timms; Rainer Cramer; Stephane Camuzeaux; Ali Tiss; Celia Smith; Brian Burford; Ilia Nouretdinov; Dmitry Devetyarov; Aleksandra Gentry-Maharaj; Jeremy Ford; Zhiyuan Luo; Alex Gammerman; Usha Menon; Ian Jacobs
Journal: Clin Chem Date: 2010-01-21 Impact factor: 8.327

10. Developing multiplexed assays for troponin I and interleukin-33 in plasma by peptide immunoaffinity enrichment and targeted mass spectrometry.

Authors: Eric Kuhn; Terri Addona; Hasmik Keshishian; Michael Burgess; D R Mani; Richard T Lee; Marc S Sabatine; Robert E Gerszten; Steven A Carr
Journal: Clin Chem Date: 2009-04-16 Impact factor: 8.327

5 in total

Introduction: Advances in protein analysis for the clinical laboratory.

Review 1. The human plasma proteome: history, character, and diagnostic prospects.

2. Can mass spectrometric protein profiling meet desired standards of clinical laboratory practice?

3. Proteomics: a new diagnostic frontier.

Review 4. Protein biomarker discovery and validation: the long and uncertain path to clinical utility.

Review 5. The blood peptidome: a higher dimension of information content for cancer biomarker discovery.

6. Quantification of thyroglobulin, a low-abundance serum protein, by immunoaffinity peptide enrichment and tandem mass spectrometry.

Review 7. The MALDI-TOF mass spectrometric view of the plasma proteome and peptidome.

8. Protein quantitation through targeted mass spectrometry: the way out of biomarker purgatory?

9. Peptides generated ex vivo from serum proteins by tumor-specific exopeptidases are not useful biomarkers in ovarian cancer.

10. Developing multiplexed assays for troponin I and interleukin-33 in plasma by peptide immunoaffinity enrichment and targeted mass spectrometry.

Review 1. Mass-spectrometry-based clinical proteomics--a review and prospective.

2. Assessing the quality and reproducibility of a proteomic platform for clinical stroke biomarker discovery.

3. Rapid magneto-enzyme-linked immunosorbent assay for ultrasensitive protein detection.

Review 4. Proteomic approaches in biomarker discovery: new perspectives in cancer diagnostics.

5. Transcriptomic and Proteomic Investigation of HSP90A as a Potential Biomarker for HCC.